C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
|
|
- きゅうた おえづか
- 5 years ago
- Views:
Transcription
1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA follow-up 2 46 PEG/R 1:1 PEG-IFN-2b + IFN-2b + IFN/R (PEG-IFN-2b 250 IFN-2b 250 ) 514 (PEG-IFN-2b 258 IFN-2b 256 ) 511 (PEG-IFN-2b 257 IFN-2b 254 ) 507 (PEG-IFN-2b 254 IFN-2b 253 ) FAS 506 (PEG-IFN-2b 254 IFN-2b 252 ) IFN C PEG-IFN-2b + C034* Genotype 1b 100 kcopies/ml HCV-RNA PEG-IFN -2b 1.5 µg/kg + 46 IFN-2b 300 IU IFN-2b 600 IU IFN PEG-IFN -2b + IFN-2b + HCV-RNA C034 PEG-IFN-2b + HCV-RNA IFN -2b + 5 IFN-2b + 41 PEG-IFN-2b + 46 PEG-IFN-2b + IFN -2b
2 C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % % 68 % 56 % n Genotype 1 C 20 40kg 100 kg 60 C Genotype 1Genotype 1a 1b HCV-RNA RT-PCR HCV 100 k IU/mL 60 ALT ALT 45 IU/L * (%)0.124 * (ng/ml)0.001 =1, 2 (-0.413) *(/mm 3 )(-0.075)2.005 * g/dl 1,500 /mm 3 10 /mm 3 Cockcroft 51 Ccr =140 (kg) /72 (mg/dl) Ccr Ccr mg/dl 110 mg/dl 126 mg/dl Hb A1c 6.5% 2 polyethylene glycol IFN IFN 30 IFN IFN HBs mmhg grade 3 601
3 C033* 3 of 7 30 C IFN HCG PEG-IFN-2b IFN-2b peginterferon alfa-2binn 1.5 µg/kg b JAN IFN-2b 600 IU (JAN) 6001,000 mg/ PEG/R PEG-IFN-2b + PEG-IFN-2b 1.5g/kg 1/ mg/ 48 IFN/R IFN-2b IFN-2b 600IU 6/ mg/
4 C033* 4 of 7 HIV IFN IL-2 C () Day 1) ) 3) 4) 5) CT X PEGR 1 IFNR 3 a) --#-- b) --#-- c) --#-- HCG --#-- HCV-RNA HCV-RNA HCV genotype HBs f) ml Day1a 2 baltast -GTPALPLDH 314 BUN HbA1C* CRP - * * 4 14 ctshft3ft4trab*tpoab* dbranched DNA probe* HCV 48 e fafppivka-ii * # Day HCV-RNA RT-PCR 24 HCV-RNA 24 HCV-RNA IFN / HCV-RNA RT-PCR 24 HCV-RNA 24 HCV-RNA HCV-RNA RT-PCR HCV-RNA HCV-RNA 603
5 C019* 5 of HCV-RNA RT-PCR 12 HCV-RNA 12 HCV-RNA IFN / 4. ALT ALT ALT ALT ALT 5. ALT ALT 24 ALT 24 ALT ALT IFN / 1. 1) 2) 3)
6 C033* 6 of [FAS PPS PPS ] IFN Wilcoxon-Mann-Whitney test Mantel-Haenszel test Fisher s exact test 1. IFN 2. HCV-RNA RT-PCR HCV ALT 3. PEG-IFN-2bIFN-2b 24 HCV-RNA 1. FAS PEG/R IFN/R -10 PEG/R IFN/R 2. PPS PPS IFN logistic regression analysis IFN HCV-RNA RT-PCR HCV ALT IFN HCV-RNA RT-PCR HCV ALT 605
7 C033* 7 of 7 PEG/R IFN/R ALT ALT 24 HCV-RNA HCV-RNA 24 HCV-RNA HCV-RNA 24 HCV-RNA HCV-RNA ALT HCV-RNA ALT MedDRA 1. skewnesskurtosis 25% 75% grade
8 PEG/R 258 IFN/R PEG/R 257 IFN/R PEG/R 1 IFN/R PEG/R 257 IFN/R PEG/R 20.2%52 /257 IFN/R 21.7%55 /254 / / PEG/R 8.9%23 /257 IFN/R 8.3%21 /254 PEG/R 8.9%23 /257 IFN/R 9.8%25 / PEG/R 257 IFN/R PEG/R 6 IFN/R 13 PEG/R 2.3%6 /257 IFN/R 3.9%10 /254 / / PEG/R 0.0%0 /257 IFN/R 0.4%1 /
9 786 * PEG-IFN-2b IFN-2b * Hb/PLT Hb/PLT 257 /Neu /Neu 21 Hb/PLT Hb/PLT /Neu /Neu PEG-IFN-2b IFN-2b ** 257 ** 254 )
10 C033* (C033*) PEG/R IFN/R PEG-IFN-2b/ IFN-2b 6MIU 6 / 1.5 µg/kg1 / MIU3 / ,000 mg/ 600-1,000 mg/ % % % % 0 0.0% 1 0.4% / / % % / / % % 1 0.4% 0 0.0% 1 0.4% 0 0.0% 1 0.4% 2 0.8% 0 0.0% 1 0.4% A 0 0.0% 4 1.6% % % % % / / 7 2.7% 4 1.6% / / % % / 1 0.4% 1 0.4% 2 0.8% 0 0.0% % % % % % % 6 2.3% % 0 0.0% 1 0.4% 0 0.0% 1 0.4% / / 0 0.0% 1 0.4% % % CHC500CSR14_1_1_4 all randomized subjects ARS Full analysis set FAS FAS Per Plotocol Set PPS FAS PPS ARS FAS ARS 514 PEG/R 258 IFN/R
11 ARS 514 PEG/R 258 IFN/R PEG/R 254 IFN/R PEG/R 4 IFN/R 3 GCP 5 PEG/R 3 IFN/R 2 2 PEG/R 1 IFN/R 1 GCP 5 IFN/R 1 / PEG/R IFN/R 3 PEG-IFN-2b 1 IFN-2b 2 IFN/R 1 PEG/R 1 ARS 514 PEG/R 258 IFN/R 256 FAS 506 PEG/R 254 IFN/R 252 FAS 8 PEG/R 4 IFN/R 4 GCP 5 PEG/R 3 IFN/R 2 2 PEG/R 1 IFN/R 1 IFN-2b 1 IFN/R 1 IFN-2b 1 IFN/R 1 FAS 506 PEG/R 254 IFN/R 252 PPS 429 PEG/R 219 IFN/R 210 PPS 77 PEG/R 35 IFN/R 42 8 PEG/R 4 IFN/R 4 2 PEG/R 1 IFN/R 1 3 PEG/R 1 IFN/R 2 17 PEG/R 6 IFN/R 11 5 PEG/R 1 IFN/R 4 70 PEG/R 32 IFN/R 38 FAS PPS ARS 507 PEG/R 254 IFN/R PEG/R /254 IFN/R 84.6%214 /253 80% PEG/R /254 IFN/R 78.3%198 /
12 C033* PEG/R n= 254 IFN/R n= % % % % % % % % % % % % % % CSR T PEG/R 600 mg / mg /142 1,000 mg /18 IFN/R 600 mg / mg /131 1,000 mg /16 PEG/R mg / mg /142 1,000 mg /18 IFN/R mg / mg /131 1,000 mg / C033* PEG/R n=254 IFN/R n=253 PEG-IFN-2b/IFN-2b 1.5 µg/kg 1.5 µg/kg 1.5 µg/kg 600MIU 600MIU 600MIU 600mg 800mg 1,000mg 600mg 800mg 1,000mg % 97.9% 100.0% 94.3% 96.9% 100.0% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % 78.9% 88.9% 72.6% 82.4% 81.3% CSR T02 611
13 FAS 506 PEG/R 254 IFN/R C033* 1 of 3 (C033*) PEG/R IFN/R (65.0%) 164 (65.1%) [Fisher's exact test] 89 (35.0%) 88 (34.9%) p = bae % % kg [Wilcoxon Mann Whit ney test] Z= p= (93.3%) 229 (90.9%) [Fisher's exact test] (6.7%) 23 (9.1%) p = % % [Wilcoxon-Mann-Whitn ey test] Z= p= kg 94 (37.0%) 106 (42.1%) [ Mantel-Haenszel 60kg 80kg 142 (55.9%) 130 (51.6%) test] 80kg 18 (7.1%) 16 2 =1.2895df= 1 (6.3%) p= % % [Wilcoxon-Mann-Whitn ey test] Z= p= (2.0%) 7 (2.8%) [ Mantel-Haenszel (19.7%) 66 (26.2%) test] (35.0%) 81 (32.1%) 2 =2.5baedf= (43.3%) 98 (38.9%) p= (21.7%) 43 (17.1%) [Fisher's exact test] 199 (78.3%) 209 (82.9%) p = (53.9%) 139 (55.2%) 91 (35.8%) 81 (32.1%) [Fisher's exact test] IFN 26 (10.2%) 31 (12.3%) p = (0.0%) 1 (0.4%) Genotype 1a 2 (0.8%) 0 (0.0%) [Fisher's exact test] 1b 252 (99.2%) 252 (100.0%) p = a1b 0 (0.0%) 0 (0.0%) 612
14 C033* of 3 (C033*) PEG/R IFN/R no fibrosis 0 (0.0%) 0 (0.0%) mild fibrosis 107 (42.1%) bae (41.3%) [ Mantel-Haenszel moderate fibrosis 109 (42.9%) 114 (45.2%) test] severe fibrosis 34 (13.4%) 30 (11.9%) 2 =0.0211df= 1 staging cirrhosis 1 (0.4%) 3 (1.2%) p= (1.2%) 1 (0.4%) None 0 (0.0%) 0 (0.0%) Minimal chronic 48 (18.9%) 49 (19.4%) hepatitis [ Mantel-Haenszel Mild chronic hepatitis 88 (34.6%) 89 (35.3%) test] Moderate chronic 102 (40.2%) 94 (37.3%) hepatitis 2 =0.0032df= 1 grading Severe chronic p= (5.1%) 19 (7.5%) hepatitis 3 (1.2%) 1 (0.4%) HCV-RNA [Wilcoxon-Mann-Whitn ey test] RT-PCR 75% Z=0.1848p= HCV 25% KIU/mL (8.7%) 16 (6.3%) (12.2%) 38 (15.1%) (28.0%) 68 (27.0%) (51.2%) 130 (51.6%) bae ALT 75% IU/L 25% (6.3%) 16 (6.3%) (47.6%) 117 (46.4%) (34.6%) 96 (38.1%) (11.4%) 23 (9.1%) [ Mantel-Haenszel test] 2 =0.0151df= 1 p= [Wilcoxon-Mann-Whitn ey test] Z= p= [ Mantel-Haenszel test] 2 =0.0007df= 1 p=
15 C033* 3 of 3 (C033*) PEG/R IFN/R [Wilcoxon-Mann-Whitn ey test] g/dl 75% Z= p= % , , , [Wilcoxon-Mann-Whitn 8,000 6,577 /mm 3 ey test] 75% 3,235 3,196 Z= p= ,614 2, % 2,042 2,065 1,376 1, [Wilcoxon-Mann-Whitn /mm 3 ey test] 75% Z= p= % CHC500CSR14_1_4_1&CSR14_1_4_6 Wilcoxon-Mann-Whitney testp= Mantel-Haenszel testp= HCV-RNA ALT 614
16 HCV-RNA HCV-RNA PEG/R /254 IFN/R /252 2 PEG/R IFN/R HCV-RNA PEG/R /254 IFN/R /252 2 PEG/R IFN/R HCV-RNA PEG/R /254 IFN/R /252 2 PEG/R IFN/R HCV-RNA PEG/R /254 IFN/R /252 2 PEG/R IFN/R HCV-RNA PEG/R IFN/R 95% IFN/R PEG/R PEG-IFN-2b+ IFN-2b+ PPS ARS FAS IFN HCV-RNA PEG/R IFN/R 95% PPS %ARS % IFN % HCV-RNA HCV-RNA C033** PEG/R n= 254 IFN/R n= 252 HCV-RNA * 95% 24 n= 254 n= (66.9%) 165 (65.5%) -6.8% 9.7% 57 (22.4%) 53 (21.0%) 27 (10.6%) 34 (13.5%) n= 254 n= (71.7%) 175 (69.4%) -5.7% 10.2% 69 (27.2%) 70 (27.8%) 3 ( 1.2%) 7 ( 2.8%) 12 n= 254 n= (47.6%) 115 (45.6%) -6.7% 10.7% 122 (48.0%) 122 (48.4%) 11 ( 4.3%) 15 ( 6.0%) 24 n= 254 n= (47.6%) 113 (44.8%) -5.9% 11.5% 122 (48.0%) 120 (47.6%) 11 ( 4.3%) 19 ( 7.5%) *PEG/R -IFN/R CSR 14_2_2_1 staging grading 615
17 HCV-RNA RT-PCR ALT / HCV-RNA IFN PEG/R /137 IFN/R /139 PEG/R /91 IFN/R /81 PEG/R /26 IFN/R /31 IFN 24 HCV-RNA HCV-RNA C033** / PEG/R IFN/R HCV-RNA *95% 59/137 (43.1%) 65/139 (46.8%) -15.4%8.0% 57/91 (62.6%) 42/81 (51.9%) -4.0%25.5% IFN 5/26 (19.2%) 6/31 (19.4%) -20.7%20.4% 0/0 (0.0%) 0/1 (0.0%) no fibrosis 0/0 (0.0%) 0/0 (0.0%) mild fibrosis 60/107 (56.1%) 55/bae (52.9%) -10.2%16.6% moderate fibrosis 50/109 (45.9%) 44/114 (38.6%) -5.7%20.2% Stagingsevere fibrosis 11/34 (32.4%) 13/30 (43.3%) -34.7%12.7% cirrhosis 0/1 (0.0%) 0/3 (0.0%) 0/3 (0.0%) 1/1 (100.0%) %-100.0% none 0/0 (0.0%) 0/0 (0.0%) minimal chronic hepatitis 20/48 (41.7%) 20/49 (40.8%) -18.7%20.4% mild chronic hepatitis 52/88 (59.1%) 46/89 (51.7%) -7.2%22.0% moderate chronic Grading 45/102 (44.1%) 41/94 (43.6%) -13.4%14.4% hepatitis severe chronic hepatitis 4/13 (30.8%) 5/19 (26.3%) -27.5%36.4% 0/3 (0.0%) 1/1 (100.0%) %-100.0% /22 (59.1%) 9/16 (56.3%) -29.0%34.7% HCV-RNA /31 (51.6%) 15/38 (39.5%) -11.3%35.6% RT-PCR /71 (38.0%) 22/68 (32.4%) -10.2%21.5% KIU/mL850 65/130 (50.0%) 67/130 (51.5%) -13.7%10.6% /72 (36.1%) 39/87 (44.8%) -24.0%6.5% /93 (51.6%) 35/85 (41.2%) -4.1%25.0% /73 (54.8%) 32/65 (49.2%) -11.1%22.2% mg/kg /16 (43.8%) 6/12 (50.0%) -43.5%31.0% /0 (0.0%) 1/3 (33.3%) 45 5/16 (31.3%) 8/16 (50.0%) -52.2%14.7% /121 (43.8%) 54/117 (46.2%) -15.0%10.3% ALT /88 (51.1%) 42/96 (43.8%) -7.0%21.8% IU/mL /29 (62.1%) 9/23 (39.1%) -3.7%49.6% 65 6/17 (35.3%) 7/23 (30.4%) -24.6%34.3% /237 (48.5%) 106/229 (46.3%) -6.8%11.3% 94/165 (57.0%) 82/164 (50.0%) -3.8%17.7% 27/89 (30.3%) 31/88 (35.2%) -18.7%8.9% Caucasian 0/1 (0.0%) 0/0 (0.0%) Asian 121/253 (47.8%) 113/252 (44.8%) -5.7%11.7% /94 (35.1%) 45/106 (42.5%) -20.8%6.1% /142 (57.7%) 63/130 (48.5%) -2.5%21.1% kg /18 (33.3%) 5/16 (31.3%) -29.4%33.5% *PEG/R -IFN/R CSR14_2_2_314_2_3_714_2_5_1 616
18 stepwise 20% stepwise HCV-RNA PEG/R staging 5%IFN/R staging grading HCV-RNA RT-PCR 5% PEG/R FAS <.0001 R 14 * stepwise IFN/R FAS <.0001 *. stepwise HCV-RNA HCV-RNA
19 HCV-RNA C033* PEG/R n=254 IFN/R n=252 5/253 (2.0%) 16/249 ( 6.4%) 23/249 (9.2%) 31/238 (13.0%) /238 (60.5%) 124/232 (53.4%) /227 (74.9%) 165/218 (75.7%) /218 (78.4%) 162/208 (77.9%) /206 (79.6%) 155/201 (77.1%) 182/251 (72.5%) 175/245 (71.4%) 131/245 (53.5%) 127/239 (53.1%) /243 (49.8%) 115/237 (48.5%) /243 (49.8%) 113/233 (48.5%) 121/244 (49.6%) 114/237 (48.1%) (CSR 14_2_6_2) PEG/R IFN/R HCV-RNA C033* 618
20 HCV-RNA HCV-RNA HCV-RNART-PCR 75% HCV-RNA HCV-RNA HCV-RNA PEG/R 100%5 /5 100%18 / %86 /121 IFN/R 75.0%12 / %16 / %65 /93 24 HCV-RNA PEG/R IFN/R 36.4%12 / %20 /49 24 HCV-RNA HCV-RNA HCV-RNA HCV-RNA C033* HCV-RNA PEG/R n=254 IFN/R n=252 n=5 n= (100.0%) 12 (75.0%) 0 (0.0%) 1 (6.3%) (CSR 14_2_6_3_2) 0 (0.0%) 3 (18.8%) n=18 n=19 18 (100.0%) 16 (84.2%) 0 (0.0%) 3 (15.8%) 0 (0.0%) 0 (0.0%) n=121 n=93 86 (71.1%) 65 (69.9%) 34 (28.1%) 24 (25.8%) 1 (0.8%) 4 (4.3%) n=33 n=49 12 (36.4%) 20 (40.8%) 21 (63.6%) 28 (57.1%) 0 (0.0%) 1 (2.0%) n=11 n=6 0 (0.0%) 0 (0.0%) 11 (100.0%) 6 (100.0%) 0 (0.0%) 0 (0.0%) n=4 n=2 0 (0.0%) 0 (0.0%) 4 (100.0%) 2 (100.0%) 0 (0.0%) 0 (0.0%) n=1 n=1 0 (0.0%) 0 (0.0%) 1 (100.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) HCV-RNART-PCR 357 PEG/R 182 IFN/R PEG/R 181 IFN/R HCV-RNART-PCR 24 PEG/R IFN/R 33.7%61 / %59 / HCV-RNA 619
21 24 PEG/R IFN/R 0%0 / %2 /115 ALT ALT PEG/R IFN/R 53.9%137 / %140 /252 ALT PEG/R -IFN/R 95% % ALT PEG/R IFN/R 70.5%179 / %165 /252 ALT PEG/R -IFN/R 95% % ALT ALT C033** PEG/R n=254 IFN/R n=252 * ALT 95% n=254 n= (70.5%) 165 (65.5%) -3.1% 13.1% 54 (21.3%) 58 (23.0%) 21 (8.3%) 29 (11.5%) 24 n=254 n= (53.9%) 140 (55.6%) -10.3% 7.1% 71 (28.0%) 58 (23.0%) 46 (18.1%) 54 (21.4%) * PEG/R -IFN/R (CSR 14_2_7_1) PEG/R IFN/R PEG/R 60% 97.2%247 / % 245 / %245 / %242 / %233 / %224 / %220 / %213 / %204 / %202 / %197 / %185 / %182 / %174 / %170 / %155 /254 IFN/R 60% 99.2%251 / %247 / %241 / %238 / %229 / %224 / %220 / %211 / %197 / %190 / %189 / %187 / %180 / %173 / %171 / % 620
22 163 /253 PEG/R IFN/R 5% PEG/R 41.7%IFN/R 3.6% PEG/R 26.0%IFN/R 2.8% PEG/R 79.5%IFN/R 67.6% PEG/R 86.6% IFN/R 74.7% PEG/R 96.5% IFN/R 87.0% PEG/R 80.3%IFN/R 71.1% PEG/R 27.2%IFN/R 18.2% PEG/R 61.0% IFN/R 52.2% PEG/R 8.3% IFN/R 0.8% PEG/R 21.3%IFN/R 14.6% PEG/R 35.0%IFN/R 29.2% PEG/R 5.9%IFN/R 0.4% PEG/R 8.3% IFN/R 3.2% PEG/R 18.9% IFN/R 13.8% IFN/R PEG/R 5% PEG/R 18.5%IFN/R 30.8% PEG/R 3.9%IFN/R 13.4% PEG/R 33.1%IFN/R 41.9% PEG/R 66.9% IFN/R 75.1% PEG/R 16.1% IFN/R 23.3% PEG/R 6.7% IFN/R 13.0% PEG/R 57.9%IFN/R 64.4% PEG/R 83.9% IFN/R 90.5% PEG/R 35.8%IFN/R 42.3% PEG/R46.1% IFN/R52.6% PEG/R28.0% IFN/R34.4% PEG/R 13.8% IFN/R 19.4% PEG/R 77.6% IFN/R 83.4% PEG/R 5.1% IFN/R 10.3% PEG/R 68.5% IFN/R 73.9% PEG/R 72.8%IFN/R 77.9% PEG/R IFN/R IFN/R PEG/R PEG/R IFN/R 5% PEG/R 19.3%IFN/R 7.1% PEG/R 28.7%IFN/R 17.8% IFN/R PEG/R 5% PEG/R 78.0%198 /254 IFN/R 73.5%186 / %158 / %147 / %73 / %45 / %49 / %18 /253 PEG/R IFN/R PEG/R IFN/R PEG/R 621
23 IFN/R PEG/R IFN/R IFN PEG/R IFN/R PEG/R / /223 IFN/R / /214 PEG/R / /223 IFN/R / /214 PEG/R / /223 IFN/R / / PEG/R IFN/R kg 60 kg 60 kg 80 kg 80 kg 100 kg 622
24 PEG/R C033*1 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 19 (7.5%) 7 (2.8%) 0 (0.0%) 26 (10.2%) 16 (6.3%) 4 (1.6%) 0 (0.0%) 20 (7.9%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 47 (18.5%) 7 (2.8%) 2 (0.8%) 56 (22.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 47 (18.5%) 5 (2.0%) 2 (0.8%) 54 (21.3%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 24 (9.4%) 10 (3.9%) 0 (0.0%) 34 (13.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 1 (0.4%) 0 (0.0%) 8 (3.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 12 (4.7%) 4 (1.6%) 0 (0.0%) 16 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 5 (2.0%) 3 (1.2%) 10 (3.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 2 (0.8%) 5 (2.0%) 2 (0.8%) 2 (0.8%) 1 (0.4%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 68 (26.8%) 51 (20.1%) 0 (0.0%) 119 (46.9%) 9 (3.5%) 3 (1.2%) 0 (0.0%) 12 (4.7%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 8 (3.1%) 7 (2.8%) 0 (0.0%) 15 (5.9%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 623
25 IFN/R C033*1 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 14 (5.5%) 3 (1.2%) 2 (0.8%) 19 (7.5%) 11 (4.3%) 1 (0.4%) 2 (0.8%) 14 (5.5%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 34 (13.4%) 8 (3.2%) 0 (0.0%) 42 (16.6%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 30 (11.9%) 7 (2.8%) 0 (0.0%) 37 (14.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 24 (9.5%) 10 (4.0%) 1 (0.4%) 35 (13.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 8 (3.2%) 2 (0.8%) 0 (0.0%) 10 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 12 (4.7%) 1 (0.4%) 0 (0.0%) 13 (5.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 13 (5.1%) 1 (0.4%) 15 (5.9%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 6 (2.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 70 (27.7%) 52 (20.6%) 0 (0.0%) 122 (48.2%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 12 (4.7%) 0 (0.0%) 18 (7.1%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 624
26 PEG/R C033*2 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 2 (0.8%) 0 (0.0%) 17 (6.7%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 5 (2.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 0 (0.0%) 8 (3.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 1 (0.4%) 0 (0.0%) 16 (6.3%) 12 (4.7%) 4 (1.6%) 0 (0.0%) 16 (6.3%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 5 (2.0%) 6 (2.4%) 0 (0.0%) 11 (4.3%) 2 (0.8%) 2 (0.8%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 625
27 IFN/R C033*2 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 9 (3.6%) 0 (0.0%) 9 (3.6%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 3 (1.2%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 27 (10.7%) 6 (2.4%) 0 (0.0%) 33 (13.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 4 (1.6%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 18 (7.1%) 1 (0.4%) 0 (0.0%) 19 (7.5%) 17 (6.7%) 0 (0.0%) 0 (0.0%) 17 (6.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 12 (4.7%) 2 (0.8%) 0 (0.0%) 14 (5.5%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 9 (3.6%) 1 (0.4%) 0 (0.0%) 10 (4.0%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 2 (0.8%) 11 (4.3%) 0 (0.0%) 13 (5.1%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 626
28 PEG/R C033*3 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 79 (31.1%) 149 (58.7%) 1 (0.4%) 229 (90.2%) 15 (5.9%) 1 (0.4%) 0 (0.0%) 16 (6.3%) 14 (5.5%) 2 (0.8%) 0 (0.0%) 16 (6.3%) 105 (41.3%) 14 (5.5%) 0 (0.0%) 119 (46.9%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 5 (2.0%) 20 (7.9%) 20 (7.9%) 0 (0.0%) 40 (15.7%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 6 (2.4%) 7 (2.8%) 0 (0.0%) 13 (5.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 19 (7.5%) 40 (15.7%) 0 (0.0%) 59 (23.2%) 57 (22.4%) 27 (10.6%) 0 (0.0%) 84 (33.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 7 (2.8%) 0 (0.0%) 11 (4.3%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9 (3.5%) 6 (2.4%) 0 (0.0%) 15 (5.9%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 2 (0.8%) 0 (0.0%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 8 (3.1%) 0 (0.0%) 9 (3.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 627
29 IFN/R C033*3 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 62 (24.5%) 173 (68.4%) 1 (0.4%) 236 (93.3%) 12 (4.7%) 3 (1.2%) 0 (0.0%) 15 (5.9%) 12 (4.7%) 3 (1.2%) 0 (0.0%) 15 (5.9%) bae (41.1%) 25 (9.9%) 0 (0.0%) 129 (51.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 17 (6.7%) 33 (13.0%) 0 (0.0%) 50 (19.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 11 (4.3%) 0 (0.0%) 26 (10.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 13 (5.1%) 49 (19.4%) 0 (0.0%) 62 (24.5%) 70 (27.7%) 36 (14.2%) 0 (0.0%) 106 (41.9%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 3 (1.2%) 0 (0.0%) 6 (2.4%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 7 (2.8%) 0 (0.0%) 9 (3.6%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 7 (2.8%) 0 (0.0%) 22 (8.7%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 3 (1.2%) 0 (0.0%) 4 (1.6%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 628
30 PEG/R C033*4 of 15 PEG/R n=254 2 (0.8%) 54 (21.3%) 198 (78.0%) 254 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 14 (5.5%) 4 (1.6%) 0 (0.0%) 18 (7.1%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 109 (42.9%) 38 (15.0%) 0 (0.0%) 147 (57.9%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 7 (2.8%) 0 (0.0%) 0 (0.0%) 7 (2.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 15 (5.9%) 29 (11.4%) 0 (0.0%) 44 (17.3%) 30 (11.8%) 26 (10.2%) 0 (0.0%) 56 (22.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (3.1%) 10 (3.9%) 0 (0.0%) 18 (7.1%) 28 (11.0%) 7 (2.8%) 0 (0.0%) 35 (13.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 6 (2.4%) 4 (1.6%) 0 (0.0%) 10 (3.9%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 629
31 IFN/R C033*4 of 15 IFN/R n=253 0 (0.0%) 67 (26.5%) 186 (73.5%) 253 (100.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 6 (2.4%) 4 (1.6%) 0 (0.0%) 10 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 109 (43.1%) 54 (21.3%) 0 (0.0%) 163 (64.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 8 (3.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 2 (0.8%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 0 (0.0%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 5 (2.0%) 0 (0.0%) 6 (2.4%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 21 (8.3%) 33 (13.0%) 0 (0.0%) 54 (21.3%) 26 (10.3%) 34 (13.4%) 0 (0.0%) 60 (23.7%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 2 (0.8%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 5 (2.0%) 7 (2.8%) 0 (0.0%) 12 (4.7%) 30 (11.9%) 19 (7.5%) 0 (0.0%) 49 (19.4%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 2 (0.8%) 0 (0.0%) 5 (2.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 3 (1.2%) 1 (0.4%) 0 (0.0%) 4 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (1.6%) 7 (2.8%) 0 (0.0%) 11 (4.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 1 (0.4%) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%) 0 (0.0%) 1 (0.4%) 6 (2.4%) 1 (0.4%) 0 (0.0%) 7 (2.8%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 630
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More informationHOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More information日本医師会雑誌第131巻第10号
B C 100 12 11 13 3 C 4 C Q&A B C 54 B B B B Q&A B B HBV 20 HBV B B B B HBV HBV HBV HBV 2 HBV HBV HBV A HBV HBV HBV HBV HBV Q37 HBV HBV HBV 1015 B B B Q51 B HBV B B HBV B HBV HBV HBV B B B HBV B HBV HBV
More informationCTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
More informationケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
More informationM1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
More information函館市_絵で見てわかる
70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183
More information「スウェーデン企業におけるワーク・ライフ・バランス調査 」報告書
1 2004 12 2005 4 5 100 25 3 1 76 2 Demoskop 2 2004 11 24 30 7 2 10 1 2005 1 31 2 4 5 2 3-1-1 3-1-1 Micromediabanken 2005 1 507 1000 55.0 2 77 50 50 /CEO 36.3 37.4 18.1 3-2-1 43.0 34.4 / 17.6 3-2-2 78 79.4
More information第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa
第 4 回血管病理研究会 日時 : 平成 20 年 0 月 0 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ). 67 2008 CRP MPO-ANCA 25IU/l 009 2 CT mpa GCA PSL 50 mg CRP MPO-ANCA mpa GCA 4 mpa ovarlap 2 TLR 2 2. 対象 方法
More informationindd
18 61 1 2011 症例報告 2010 5 13 2010 12 20 A Case of Varicella with Severe Back Pain in a Patient with Systemic Lupus Erythematosus RIE SAITO, KIORI YANO, FUMIKO KATSUSHIMA, HARUYO IWADATE, HIROKO KOBAYASHI,
More informationuntitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
More information長崎県県央保健所事業概要
P1 P2~P3 P4 P5 P7~P10 P11~P40 P41~P174 P175~P179 P181~P212 271,417 2 3 4 5 5 7 8 9 10 12 13 14 15 16 18 19 2,506 365 293 5 20 2 4 123 4 17 1 2 143 351 5 3 18 40 10 475 3 2 22 22 66 1 13 18 31 10
More informationuntitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
More informationII (No.2) 2 4,.. (1) (cm) (2) (cm) , (
II (No.1) 1 x 1, x 2,..., x µ = 1 V = 1 k=1 x k (x k µ) 2 k=1 σ = V. V = σ 2 = 1 x 2 k µ 2 k=1 1 µ, V σ. (1) 4, 7, 3, 1, 9, 6 (2) 14, 17, 13, 11, 19, 16 (3) 12, 21, 9, 3, 27, 18 (4) 27.2, 29.3, 29.1, 26.0,
More informationuntitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
More information肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
More information64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
More information* 1 6 ( ) 20 GOT GPT ( ) 59 3 CT F D T3 *
-259 3101 * 1 6 () 20 GOTGPT 3 155169 2 5 () 59 3 CT 129 59 F D T3 * -- 428 - -259 3101 * 3 5 4 6 () 159 NOS () 158 159 R 4U T3 500ml 2ml 2g 100ml 25mg PL 162 152 152 37 1630 92mg/dl PL 3g/ 3 300mg/ 3
More information商品リストVol09_01
Asian Ethnic Foods Vol.9 2796 406 180 104 200ml / 12 200ml / 12 190g / 12 2B/L 250ml / 12 2B/L 8934874 112205 189 34874 11220 2 8850045 111016 9556156 036765 077521 273312 200 77521 27331 6 210 280 200
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More information10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
More information23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
More informationPSCHG000.PS
a b c a ac bc ab bc a b c a c a b bc a b c a ac bc ab bc a b c a ac bc ab bc a b c a ac bc ab bc de df d d d d df d d d d d d d a a b c a b b a b c a b c b a a a a b a b a
More informationWBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More information2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
More information慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
More information中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
More informationuntitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
More informationSlide 1
B 型慢性肝炎に対するペグインターフェロ ン療法の有効性 安全性について 関西労災病院 林紀夫 緒言 ペグインターフェロン (PEG-IFN)α-2a は,AASLD, EASL, APASL の HBV マネジメントガイドラインで B 型慢性肝炎の治療に対して第一選択薬として推奨されているが 1-3, 本邦では現在, B 型慢性肝炎に対して承認されていない 核酸アナログ製剤とは異なり, 一定の投与期間で持続的な効果を示すことが報告されている
More informationI
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
More information- 9 91, (2006)
Case study level Ma Management of testicular cancer - 9 91, 10 0.7 2.4 (2006) 20 30 20 20-40 AFP -hcg -hcg AFP TNM T ptx pt0 ptis pt1 / pt2 / pt3 / pt4 / N NX N0 N1 2cm 1 2cm N2 2cm 5cm 1 5cm N3 5cm TNM
More informationA5_Catalog-US-JN_ indd
66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **
More informationニトロトルエン
4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6
More information200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
More informationuntitled
---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14
More informationuntitled
3 ...I-1... I-1... I-2... I-12... I-13... II-1...II-1...II-1...II-2...II-4...II-4...II-29...II-42...II-47...II-55 IT...II-70...II-77...II-79...II-79...II-84...II-86...II-90...II-91...II-91...II-93...II-100
More informationEPSON LP-8900ユーザーズガイド
3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32
More information/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
More informationBA_kanen_QA_zenpan_kani_univers.indd
その他 B 型肝炎 15% C 型肝炎 68% 41 706 168 66 19 12 肝 には の か 脂肪肝 の で る () という も りま の く い 肝 の肝細胞のなかに 脂肪の く がこ なにたまっ いま 類洞 正常な肝臓 腸管からの栄養や不要物が流れていく 肝細胞 正常な肝臓 脂肪肝の始まり 類洞 腸管からの栄養や不要物が流れていく 類洞 過剰な脂質 糖質の流入 肝細胞 肝細胞のなかに中性脂肪がたまり始める
More information112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6 7 B 2 NTT 2012 6
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 111 53 8 8 1. Ph-ALL Liposomal amphotericin B 1 2. CBT MCFG L-AMBAML 2 112 54 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 Apr. 2013 8 2005 3 10 8 2012 6
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More informationml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
More information高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More information日本呼吸器学会雑誌第44巻第6号
Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl
More informationph
14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................
More information1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
More information橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
More information無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
More informationスライド 1
第 9 回肝炎治療戦略会議 212.9.4 2. C 型肝炎に対するこれまでの治療法 の変遷と現状 今後の展望について 武蔵野赤十字病院消化器科泉並木 IL28B SNP の genotype の分布と頻度 rs899917 世界分布 IL28B 遺伝子のタイプ (n = 865) 効きにくい (Minor type) TG 25.3% GG 1.6% TT 73.1% Tomas D et al.
More informationuntitled
1 2 2 2 3 3 4 4 5 9 6 9 7 10 8 13 1 34 2 46 1 46 2 51 3 54 4 58 5 64 72 74 76 78 80 81 82 86 90 94 98 99 99 100 104 106 108 112 113 114 115 116 117 118 119 119 120 121 122 123 123 124 124 125 125 126 126
More informationAD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
More information2 CSR -
20312-1819 2 CSR - 3 1 2 3 ( ) 4 - A 5 B C 5. 6 7 8 9 8. - 9. - 58 9 8 25 16, 7 5 2,500 ( ) 0751,920 07125,2000815,700 10 11 10. - - 12 13 - - 14 13. - - 15 1 61 171228 1843 16F 1 80 25 55 ( 3-21-5 http://akan-nt.or.jp
More informationuntitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
More informationC 型慢性肝炎に対するテラプレビルを含む 3 剤併用療法 の有効性 安全性等について 肝炎治療戦略会議報告書平成 23 年 11 月 28 日
C 型慢性肝炎に対するテラプレビルを含む 3 剤併用療法 の有効性 安全性等について 肝炎治療戦略会議報告書平成 23 年 11 月 28 日 C 型慢性肝炎に対するテラプレビルを含む 3 剤併用療法の 有効性 安全性等について 1. 有効性及び対象について セログループ 1 のC 型慢性肝炎に対する ペグインターフェロン リバビリン及びテラプレビル3 剤併用療法 ( 以下単に 3 剤併用療法 という
More information21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
More informationuntitled
Data cleaning Original datan=8479 NCC/ptkgN=7958 NCC10x10E628 8139 NCC/kgPage 1-2) Covariate cleaningcovariate Page Page5-8 Kaplan-Meier method, Log-rank, Cox hazard model Overall survival Cumulative incidence
More informationuntitled
HCV 150 HCV 13 3 13 4 13 8 14 2 14 2 14 8 15 3 15 8 17 3 7 8 18 3 ----- i Q1 1 Q2 1 Q3 1 Q4 2 Q5 3 Q6 3 Q7 3 Q8 4 Q9 4 Q10 : 5 6 Q1 6 Q2 7 Q3 7 8 Q4 8 Q5HCV 8 Q6HCV 9 Q7HCV 9 Q8NAT 10 Q9 10 Q10 11 Q11
More informationA B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
More information1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC 4.310 3 ml Syphilis TPAb Alb 2.7 g dl RBC30210 4 ml HBsAg T. bil 2.3 mg dl Hb 11 g dl
2012; 18: 200 207 Necropsy 1 1 1 2 65 11 autoimmune hepatitisaih 14 21 1 5 13 Necropsy CHF1 A1 Kupffer cell hemosiderin Berlin blue KEY WORDS: hemochromatosis, autoimmune hepatitis, liver cirrhosis, necropsy
More informationMicrosoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
More information/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More informationMicrosoft Word - 第2回海外勤務健康管理抄録の表紙他.doc
第 2 回 海 外 勤 務 者 健 康 管 理 研 修 会 平 成 19 年 3 月 10 日 ( 土 ) (14 時 ~17 時 ) ( 独 ) 労 働 者 健 康 福 祉 機 構 大 阪 労 災 病 院 管 理 棟 3F 大 ホール 591-8025 大 阪 府 堺 市 北 区 長 曾 根 町 1179 番 地 の3 共 催 ( 社 ) 大 阪 府 医 師 会 ( 社 ) 日 本 産 業 衛 生
More information橡DI月報178.PDF
2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More informationBIT -2-
2004.3.31 10 11 12-1- BIT -2- -3-256 258 932 524 585 -4- -5- A B A B AB A B A B C AB A B AB AB AB AB -6- -7- A B -8- -9- -10- mm -11- fax -12- -13- -14- -15- s58.10.1 1255 4.2 30.10-16- -17- -18- -19-6.12.10
More information(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
More information1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
More information20-121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More information[] 1
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
More informationuntitled
30803040 1015 1 2 3 4 5 6 60 7 8 [ ] [] [ ] / 9 10 [] [] [] / () 11 12 61 13 Borg 14 15 16 mm mm 17 () BMI 200mg/dl 18 Anderson 200mmHg 120mmHg 40mmHg 20mmHg 62 AED 19 20 () 21 22 23 24 63 25 26 27 28
More information日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
More information生化学検査 臨床検査基準値一覧 近畿大学病院 (1) 検査項目 基準値 単位 検査項目 基準値 単位 CRP mg/dl WBC /μl Na mmol/l M RBC K mmol/l F 3.86-
生化学検査 近畿大学病院 (1) CRP 0.00-0.14 WBC 3.3-8.6 10 3 /μl Na 138-145 mmol/l M 4.35-5.55 RBC K 3.6-4.8 mmol/l F 3.86-4.92 10 6 /μl Cl 101-108 mmol/l M 13.7-16.8 HGB g/dl Ca 8.8-10.1 F 11.6-14.8 Pi 2.7-4.6 液 M
More information日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
More information16 8020
ペ-ジ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 8020 16 8020 681 40 59.713.3 292 3095 328 2984 620 CPI CPI CPI 0 1 2,3,4 6,9 1035 433 normal 34mild 24moderate 18severe 2466 42 CPI 23 CPI 0 1 CPI normal mild
More information23 3 11 24 21 24 25 4 28 4 2 7 161 2,692 28 12 14 18 18 380 5 3 1 27 21 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213 640 416 82,979
More information17-05 THUNDERBIRD SYBR qpcr Mix (Code No. QPS-201, QPS-201T) TOYOBO CO., LTD. Life Science Department OSAKA JAPAN A4196K
17-05 THUNDERBIRD SYBR qpcr Mix (Code No. QPS-201, QPS-201T) TOYOBO CO., LTD. Life Science Department OSAKA JAPAN A4196K - 18 - [1] 1 [2] 2 [3] 3 [4] 5 [5] : RNA cdna 13 [6] 14 [7] 17 LightCycler TM Idaho
More information8 300 mm 2.50 m/s L/s ( ) 1.13 kg/m MPa 240 C 5.00mm 120 kpa ( ) kg/s c p = 1.02kJ/kgK, R = 287J/kgK kPa, 17.0 C 118 C 870m 3 R = 287J
26 1 22 10 1 2 3 4 5 6 30.0 cm 1.59 kg 110kPa, 42.1 C, 18.0m/s 107kPa c p =1.02kJ/kgK 278J/kgK 30.0 C, 250kPa (c p = 1.02kJ/kgK, R = 287J/kgK) 18.0 C m/s 16.9 C 320kPa 270 m/s C c p = 1.02kJ/kgK, R = 292J/kgK
More information051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
More informationDynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
More informationスライド 1
虎の門病院分院川崎 B 型肝炎に対するこれまでの治療法の変遷と現状 今後の展望について 分院 虎の門病院肝臓センター熊田博光 2012.9.4 厚労省内 虎の門病院本院東京 B 型慢性肝炎の治療の目標 発癌抑制 HBs 抗原の陰性化 無治療 B 型肝硬変 82 例の HBV-DNA の動向と相対的な肝癌発癌率 肝癌発癌率 100 (%) 1990 年以前に診断され IFN 未使用の B 型肝硬変 観察終了または発癌確認までの
More information13,825,228 3,707,995 26.8 4.9 25 3 8 9 1 50,000 0.29 1.59 70,000 0.29 1.74 12,500 0.39 1.69 12,500 0.55 10,000 20,000 0.13 1.58 30,000 0.00 1.26 5,000 0.13 1.58 25,000 40,000 0.13 1.58 50,000 0.00 1.26
More information2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
More information九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
More information